CervoMed Inc. (CRVO) Stock Forecast & Price Target
CervoMed Inc. · NASDAQ
$2.65+0.01 (+0.57%)
15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering CervoMed Inc, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $11.00 to $31.00 (about 2.8x), a sign of real disagreement on valuation. The average target of $21.20 sits 702% above the current $2.65. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.51 next quarter toward $-1.48 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Strong Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to CervoMed Inc.
As of Aug, 6 of 6 firms rate CRVO a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CRVO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.51
Range $-0.75 – $-0.11 · 4 analysts · -42% YoY
Next period, 4 analysts expect CervoMed Inc. to earn $-0.51 a share (range $-0.75 – $-0.11), versus $-0.88 a year earlier. Full-year consensus is $-2.20, growing to $-1.48 the year after.
REVENUE · NEXT QUARTER
$83.3K
Range $0 – $500.0K · 4 analysts · +855% YoY
Revenue is expected to reach $83.3K (range $0 – $500.0K), +854.5% year-over-year. Full-year consensus is $133.3K, rising to $833.3K next year.
Top analysts covering CervoMed Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CRVO.
#1
Daniil Gataulin
Chardan Capital · Rank #24
Buy
$21.00+694.0% to target
Overall win rate
58%
+ Follow
#2
PS
Pete Stavropoulos
Cantor Fitzgerald · Rank #274
Buy
No targeton CRVO
Overall win rate
35%
+ Follow
#3
Sumant Kulkarni
Canaccord Genuity · Rank #287
Buy
$18.00+580.5% to target
Overall win rate
41%
+ Follow
#4
Raghuram Selvaraju
HC Wainwright & Co. · Rank #294
Buy
$25.00+845.2% to target
Overall win rate
37%
+ Follow
#5
Jason Kolbert
D. Boral Capital · Rank #407
Buy
$31.00+1072.0% to target
Overall win rate
22%
+ Follow
CRVO stock forecast FAQ
What is CRVO's average 12-month price target?+
The 5 analysts with a live target average $21.20 for CervoMed Inc. over the next 12 months, ranging from a $31.00 high to a $11.00 low.
Is CRVO stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CRVO?+
The Street-high target is $31.00 (D. Boral Capital), and the Street-low is $11.00 (Roth Capital). The average of all 5 active targets is $21.20.
How many Wall Street analysts cover CRVO?+
6 analysts have an active rating on CervoMed Inc., and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering CRVO?+
Among analysts who currently cover CRVO, Daniil Gataulin of Chardan Capital has the strongest overall Quantellect track record (Rank #24). Their current call is Buy with a $21.00 target.
What is CervoMed Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.51 per share (range $-0.75 – $-0.11) across 4 analysts. Full-year EPS is projected at $-2.20, rising to $-1.48 the following year.
How much revenue is CervoMed Inc. expected to report next quarter?+
Consensus revenue is $83.3K (range $0 – $500.0K). Full-year revenue is projected at $133.3K, growing to $833.3K next year.
Have analysts been upgrading or downgrading CRVO lately?+
As of Aug, 6 of 6 firms rate CRVO a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CRVO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
